News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,033 Results
Type
Article (467)
Company Profile (6)
Press Release (17560)
Section
Business (4938)
Career Advice (28)
Deals (971)
Drug Development (2313)
Employer Resources (2)
FDA (639)
Job Trends (627)
News (9093)
Policy (937)
Tag
2024 BioCapital Digital (1)
2024 Biotech Bay Standard (1)
2024 Pharm Country Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Elite (1)
Academia (43)
Academic (1)
Alliances (1066)
Alzheimer's disease (17)
Antibody-drug conjugate (ADC) (7)
Approvals (667)
Artificial intelligence (1)
Autoimmune disease (1)
Bankruptcy (7)
Best Places to Work (631)
Biosimilars (6)
Biotechnology (2)
Bladder cancer (6)
Breast cancer (14)
Cancer (130)
Cardiovascular disease (5)
Career advice (23)
CAR-T (8)
Cell therapy (16)
Cervical cancer (2)
Clinical research (2039)
Collaboration (26)
Compensation (6)
COVID-19 (32)
CRISPR (1)
C-suite (4)
Cystic fibrosis (1)
Data (88)
Diabetes (12)
Diagnostics (151)
Drug discovery (4)
Duchenne muscular dystrophy (1)
Earnings (2364)
Editorial (2)
Employer branding (2)
Employer resources (2)
Events (2945)
Executive appointments (12)
FDA (694)
Featured Employer (2)
Funding (7)
Gene editing (1)
Gene therapy (8)
GLP-1 (20)
Government (155)
Guidances (2)
Healthcare (644)
Immunology and inflammation (1)
Indications (3)
Infectious disease (32)
Inflammatory bowel disease (4)
Intellectual property (4)
Interviews (2)
IPO (482)
Job creations (49)
Job search strategy (22)
Layoffs (5)
Legal (149)
Liver cancer (1)
Lung cancer (41)
Lymphoma (13)
Manufacturing (8)
MASH (2)
Medical device (464)
Medtech (464)
Mergers & acquisitions (512)
Metabolic disorders (23)
Neurodegenerative disease (3)
Neuropsychiatric disorders (1)
Neuroscience (42)
NextGen: Class of 2025 (185)
Non-profit (43)
Northern California (54)
Now hiring (2)
Obesity (9)
Opinion (3)
Ovarian cancer (7)
Pain (2)
Pancreatic cancer (3)
Parkinson's disease (21)
Patents (5)
Patient recruitment (3)
People (1302)
Pharmaceutical (2)
Phase I (523)
Phase II (895)
Phase III (836)
Pipeline (45)
Postmarket research (46)
Preclinical (149)
Press Release (8)
Radiopharmaceuticals (9)
Rare diseases (9)
Real estate (124)
Recruiting (1)
Regulatory (721)
Research institute (35)
Resumes & cover letters (5)
Schizophrenia (3)
Series A (2)
Series B (2)
Service/supplier (1)
Sickle cell disease (1)
Southern California (82)
Startups (67)
Stomach cancer (1)
Supply chain (1)
United States (641)
Vaccines (16)
Weight loss (2)
Date
Today (2)
Last 7 days (23)
Last 30 days (88)
Last 365 days (1113)
2025 (327)
2024 (1207)
2023 (1399)
2022 (2051)
2021 (1945)
2020 (1816)
2019 (1406)
2018 (984)
2017 (772)
2016 (726)
2015 (813)
2014 (564)
2013 (541)
2012 (565)
2011 (563)
2010 (402)
Location
Africa (18)
Arizona (3)
Asia (2174)
Australia (236)
California (153)
Canada (80)
China (53)
Colorado (2)
Connecticut (7)
Delaware (9)
Europe (2190)
Florida (19)
Idaho (2)
Illinois (70)
Japan (10)
Kansas (2)
Kentucky (2)
Maryland (35)
Massachusetts (81)
Michigan (2)
Minnesota (12)
Nevada (2)
New Jersey (71)
New York (44)
North Carolina (14)
Northern California (54)
Oregon (1)
Pennsylvania (88)
Rhode Island (1)
South America (18)
South Carolina (1)
Southern California (82)
Tennessee (10)
Texas (8)
Virginia (1)
Washington D.C. (1)
Washington State (12)
Wisconsin (1)
18,033 Results for "gc aesthetics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
New Independent Clinical Study Showcases Safety and Efficacy of GC Aesthetics’ PERLE Breast Implant
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce that its breast implant, PERLE™, has been featured in a recent independent peer-reviewed article published in the Aesthetic Surgery Journal Open Forum.
January 26, 2024
·
2 min read
Press Releases
GC Biopharma Receives MFDS Approval for World’s First Recombinant Anthrax Vaccine
April 9, 2025
·
3 min read
Earnings
AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.
February 3, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies
April 21, 2025
·
1 min read
Press Releases
GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025
February 11, 2025
·
3 min read
Policy
FDA Grants Fast Track Designation to GCBP and Novel Pharma’s GC1130A
GC Biopharma and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA treatment, GC1130A.
June 10, 2024
·
4 min read
Press Releases
GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC
January 23, 2025
·
1 min read
Policy
GC Biopharma/Novel Pharma’s Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma and Novel Pharma announced that its jointly developed MPS IIIA ‘GC1130A’ treatment has received FDA IND approval.
May 20, 2024
·
2 min read
Policy
GC Biopharma/Novel Pharma’s Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
GC Biopharma and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug application for their jointly developed MPSIIIA treatment, GC1130A.
May 21, 2024
·
2 min read
Business
GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group
GC Cell, a fully integrated cell and gene therapy pioneer, is proud to announce the establishment of an MOU for strategic partnership with Bifarma, a frontrunner in stem cell therapy within Indonesia with comprehensive capabilities in R&D, GMP-compliant manufacturing, and the commercialization of cell therapies.
June 19, 2024
·
4 min read
1 of 1,804
Next
